Dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders


Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms of severe and complicated obesity through the MetAP2 pathway. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare forms of obesity. Zafgen's lead product candidate is ZGN-1061, which is a novel, first-in-class, twice-weekly subcutaneous injection. Zafgen is also developing ZGN-839, a liver-targeted MetAP2 inhibitor, for the treatment of nonalcoholic steatohepatitis, or NASH, and abdominal obesity. Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients affected by metabolic diseases.


Year Invested: 2007
Location: Cambridge, Mass.
Visit: www.zafgen.com

Recent News

June 13, 2017
Zafgen To Present At The JPM Securities Life Sciences Conference

June 10, 2017
Zafgen Presents New Data Highlighting Potential Of ZGN-1061 For The Treatment Of Type 2 Diabetes And Obesity At The American Diabetes Association's 77th Annual Scientific Sessions

June 6, 2017
Zafgen To Present Two Late-Breaking Abstracts for ZGN-1061 At The American Diabetes Association 77th Scientific Sessions

Read More News

Associated Team Members

Kevin Starr
Partner